EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase IV)Open Access · CC BY 4.0

Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV

Abraham Saborido-Alconchel, Ana Serna-Gallego, Luis E Lopez-Cortes iD, María Trujillo-Rodriguez, Juan Manuel Praena-Fernandez, Montserrat Dominguez-Macias, Carmen Lozano, Esperanza Muñoz-Muela, Nuria Espinosa, Cristina Roca-Oporto, Cesar Sotomayor, Marta Herrero und 2 weitere

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad245 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Abraham Saborido-Alconchel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Sevilla, Spain. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla, ViiV Healthcare, Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This was a substudy of a Phase IV, randomized clinical trial (ClinicalTrials.gov identifier: NCT04295460) aiming to compare the activity of dolutegravir/lamivudine versus dolutegravir plus tenofovir alafenamide/emtricitabine (DTG + TAF/FTC) in the male genital tract.

Methods

Participants were asymptomatic adults without sexually transmitted diseases, treatment-naive people living with HIV (PLWH), with CD4+ T cell counts >200 cells/mm3 and plasma HIV-1-RNA levels >5000 and <500 000 copies/mL, randomized (1:1) to DTG + TAF/FTC or dolutegravir/lamivudine. Blood plasma (BP) and seminal plasma (SP) were collected at baseline and Weeks 4, 8, 12 and 24. HIV-1-RNA was measured in BP and SP using the Cobas 6800 system (Roche Diagnostics) with a lower detection limit of 20 copies/mL. The primary efficacy endpoint was the proportion of subjects with undetectable SP HIV-1-RNA at Week 12 by intention-to-treat analysis.

Results

Fifteen participants in the DTG + TAF/FTC and 16 in the dolutegravir/lamivudine arms were analysed, with basal SP viral load of 4.81 (4.30–5.43) and 4.76 (4.09–5.23), P = 0.469, respectively. At Week 12, only one participant in each treatment arm had a detectable SP HIV-1-RNA (DTG + TAF/FTC, 141 copies/mL; dolutegravir/lamivudine, 61 copies/mL). Based on the estimated means, there was no significant difference in the decay of HIV-1-RNA in both BP and SP over time between the two arms of treatment (F = 0.452, P = 0.662, and F = 1.147, P = 0.185, respectively).

Conclusions

After 12 weeks of treatment, there were no differences in the percentage of undetectable SP HIV-1-RNA in naive PLWH who started dolutegravir/lamivudine compared with DTG + TAF/FTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsAnti-HIV AgentsAdultHumansMaleLamivudineSemenKineticsDrug Therapy, CombinationEmtricitabineHeterocyclic Compounds, 3-RingPyridonesOxazinesRNA, ViralDolutegravirAdenineTenofovir

Substanzen

LamivudineEmtricitabineHeterocyclic Compounds, 3-RingPyridonesOxazinesRNA, ViralAnti-HIV AgentsDolutegraviremtricitabine tenofovir alafenamideAdenine

Autor:innen und Institutionen

  • Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Instituto de Biomedicina de Sevilla / Departamento de Medicina, Universidad de Sevilla / CSIC, Sevilla, Spain.
  • Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Departamento de Estadística e Investigación Operativa, Facultad de Ciencias, Universidad de Granada, Granada, Spain.

ORCID-Profile: Luis E Lopez-Cortes, Alicia Gutierrez-Valencia, Luis F Lopez-Cortes

Förderung

  • Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
  • ViiV Healthcare
  • Ministerio de Ciencia e Innovación
  • European Regional Development Fund

Zitieren

APA

Saborido-Alconchel, A., Serna-Gallego, A., Lopez-Cortes, L. E., Trujillo-Rodriguez, M., Praena-Fernandez, J. M., Dominguez-Macias, M., Lozano, C., Muñoz-Muela, E., Espinosa, N., Roca-Oporto, C., Sotomayor, C., Herrero, M., Gutierrez-Valencia, A., & Lopez-Cortes, L. F. (2023). Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad245

Vancouver

Saborido-Alconchel A, Serna-Gallego A, Lopez-Cortes LE, Trujillo-Rodriguez M, Praena-Fernandez JM, Dominguez-Macias M, et al. Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad245

BibTeX
@article{SaboridoAlconchel2023,
  author = {Saborido-Alconchel, Abraham and Serna-Gallego, Ana and Lopez-Cortes, Luis E and Trujillo-Rodriguez, María and Praena-Fernandez, Juan Manuel and Dominguez-Macias, Montserrat and Lozano, Carmen and Muñoz-Muela, Esperanza and Espinosa, Nuria and Roca-Oporto, Cristina and Sotomayor, Cesar and Herrero, Marta and Gutierrez-Valencia, Alicia and Lopez-Cortes, Luis F},
  title = {Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad245}
}
Kostenlos starten →